1 / 52

Interstitial Lung Disease

Interstitial Lung Disease. David S. Goya, DO, FCCP, FACP Kaiser Permanente Medical Center Santa Clara, California. Introduction.

keiki
Download Presentation

Interstitial Lung Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Interstitial Lung Disease David S. Goya, DO, FCCP, FACP Kaiser Permanente Medical Center Santa Clara, California

  2. Introduction • Interstitial lung disease (ILD) comprise of a diverse group of lung infiltrates that cause disruption of alveolar structures & have common clinical, radiographic & physiological consequences

  3. Introduction • Interstitium of the lung refers to the space interposed between the basement membranes of the alveolar lining epithelium & capillary endothelium

  4. Etiology • Over 100 causes of interstitial lung disease • 2/3 of causes have no know cause • Classified based on their clinical, radiographic & pathological features

  5. Interstitium • Space contains connective tissue elements consisting of collagen, proteoglycans, glycoproteins, noncollagenous proteins, fibronectin & laminin • Interstitial macrophages, fibroblast & myofibroblast • Participate in lung repair • Can stimulate & contribute to scarring & injury

  6. Interstitium • Anatomic boundaries of the interstitium include the alveolar epithelial lining cells & adjacent capillary network • Alveolar lumen is part of interstitium • Anatomy of interstitium can be altered by inflammatory cells, proliferation of fibroblast or disordered collagen deposits

  7. Incidence • 100,000 hospital admissions a year • 15% of pulmonary practice • Incidence of ILD varies with disease entities • Scleroderma 100% • Rheumatoid arthritis 33% • Sarcoidosis 33% • Idiopathic pulmonary fibrosis 30-40%

  8. Classification of Interstitial Lung Disease • Occupational/Environmental • Drugs & Poisons (chemo) • Connective Tissue Disease (SLE, RA…) • Idiopathic Interstitial Lung Disease • Infection (can give appearance of ILD) • Other Systemic Disease – i.e sarcoidosis

  9. Occupational/Environmental • Silicosis • Asbestos • Coal workers’ pneumonconiosis • Berylliosis • Stannosis (tin) • Polyvinyl chloride pneumonitis • Humidifer Lung – hypersensitivity -

  10. Drug Induced Interstitial Lung Disease • Nitrofurantoin - antibiotics • Amiodarone – cardiologist love this for Afib, aflutter, Vtac, Vfib and refractory rhythm (smurf drug) • Gold • Penicillamine • Dilantin • Bleomycin • Cytoxan • Radiation – breast cancer tx • Bromocryptine • Methotrexate

  11. Connective Tissue Disease • Scleroderma • Systemic Lupus erythematosis – ILD in women • Rheumatoid Arthritis – ILD in men • Primary Sjogrens Syndrome • Mixed Connective Tissue Disease • Polymyositis-Dermatomyositis

  12. Idiopathic Interstitial Pneumonias • Initially thought to be the same disease with different stages of idiopathic pulmonary fibrosis • Idiopathic Interstitial pneumonias have been recently reclassified into 4 categories • Usual Interstitial Pneumonia (UIP) • Nonspecific interstitial pneumonia (NSIP) • Desquamative interstitial pneumonia • Acute interstitial pneumonia

  13. 5 Most Common Interstitial Lung Disease • Usual interstitial pneumonia • Nonspecific interstitial pneumonia • Collagen Vascular Disease • Hypersensitivity Pneumonitis • Sarcoidosis

  14. Pathogenesis • Injury to the alveolar-capillary epithelial surface • Agents can reach the lung via airway or circulation • Not known whether genetics predispose individuals • Injury is severe or persistent healing will be inhibited

  15. Pathogenesis • Initial step appears to be injury to lung cells by an unknown mechanism • Following injury, there is an influx of inflammatory & immune effector cells • Proliferation of type 2 epithelial cells • Attempt to restore integrity of epithelial surface • Synthesize a variety of matrix components & release complement & cytokines

  16. Pathogenesis • Inflammatory cells are attracted to area & releasing proteolytic enzymes & oxygen free-radicals • Major requirement for injury is continued exposure to inciting agent • Persistence of inflammatory cells/immune effector cells eventually lead to loss of alveolar gas exchange units due to honey-combing & fibrosis • Genetic component

  17. Pathogenesis

  18. Clinical Presentation • History • Past, Occupational & Family History • Physical Examination

  19. History • Typical patients are middle aged presenting with progressive dyspnea & nonproductive cough • Other symptoms are dependent on underlying process • Fever, weight loss, fatigue, myalgias & arthralgias

  20. History • Most patients report chronic & progressive symptoms • Several diseases states have a more rapid presentation of symptoms (days-weeks) • Fever, leukocytosis & diffuse radiographic infiltrates suggest atypical pneumonia - days • BOOP, hypersensitivity pneumonitis, eosinophilic pneumonia, diffuse alveolar syndrome - weeks

  21. Past, Occupational & Family History • Detailed & life-long occupational history must be obtained • Long latency period from time to exposure to disease • Environmental antigens & occupational exposure may lead to hypersensitivity pneumonitis

  22. Past, Occupational & Family History • Heredity • Autosomal dominant form of IPF-Tuberous sclerosis & Neurofibromatosis • Autosomal recessive form of IPF-Gaucher’s Disease, Niemann-Pick & Hermansky-Pudlack syndrome

  23. Past, Occupational & Family History • Sex • Lymphangioleiomyomatosis occurs only in premenopausal women – 100% exclusive • Interstitial lung disease of connective tissue disorders affect woman more often than males • Exception is Rheumatoid arthritis • Pneumoconiosises affect men more often – women don’t work as hard

  24. Physical Examination • Characteristic finding is bibasilar rales • Clubbing of fingers are common in IPF • Rare in Sarcoidosis • Signs of pulmonary hypertension & cor pulmonale are generally seen only in advanced diseases

  25. Diagnostic Test • Chest Radiography • High Resolution CT • Pulmonary Function Testing • Bronchoscopy/Bronchoalveolar Lavage • Lung Biopsy

  26. Chest Radiography • CXR is useful in suggesting the presence but not the stage of ILD • 10% of CXR maybe normal in ILD • Most common radiographic pattern are reticular or a reticulonodular pattern • Honey-combing is a late finding • Pleural disease is uncommon in IPF • Suggestive of connective tissue disease • TQ in a women think of lymphangionmyelot….

  27. High Resolution CT scan • Better resolution than conventional CT • Provide better resolution of pulmonary parenchyma & detects early interstitial lung disease • Patterns can strongly suggest presence of specific ILD • Direct biopsies

  28. Pulmonary Function Testing • Can not distinguish an inflammatory stage from fibrosis or honey-combing • Classic findings are consistent with Restrictive Ventilatory Defect • Reduced vital capacity & total lung capacity

  29. Pulmonary Function Testing • Uncommon to have an obstructive defectBronchiolitis obliterans or endobronchial sarcoidosis • Diffusion capacity is reduced due to loss of capillary bed • May precede abnormalities in lung volumes • ABG maybe normal or reveal hypoxemia due to ventilation & perfusion mismatch

  30. Bronchoalveolar Lavage • Technique conducted by wedging bronchoscope into a subsegmental bronchus • Saline is instilled & aspirated for cytology & culture • Characterize the quantity of the inflammatory & immune effector cells • Lymphocytes-hypersensitivity pneumonitis & sarcoidosis • Neutrophils increased in IPF & asbestosis

  31. Lung Biopsy • Provides a more accurate diagnosis • Exclude neoplastic & infectious process • Identify a more treatable process than originally suspected • Provide a better assessment of disease activity

  32. Lung Biopsy • Biopsies should be large quantity of tissue from 2 sites in an area of involved & normal lung • Bronchoscopy • Video Assisted Thorascopy (VAT) • Decision to proceed with bronchoscopy or VAT depends on findings of HRCT

  33. Lung Biopsy • Bronchoscopy maybe the initial procedure of choice • Good yield: • Sarcoidosis • Hypersensitivity pneumonitis • Eosinophilic pneumonia • Lymphangitic Carcinomatosis • Bronchoalveolar lavage can aid in diagnosing eosinophilic pneumonia, hypersensitivity pneumonitis, sarcoidosis & alveolar proteinosis

  34. Lung Biopsy • VATS lung biopsy yields a specific diagnosis approximately 85% of cases • Useful in diagnosing UIP, Nonspecific interstitial pneumonia, desquamative interstitial pneumonia, eosinophic granuloma, • Can only performed once

  35. Management of Interstitial Lung Disease

  36. Management of Interstitial Lung Disease • Many of the ILDs are not responsive to therapy • Major goal of therapy • Identify & aggressively treat the inflammatory process • Removal of the offending agent • No accurate or specific method available to stage the intensity of the alveolitis in a serial fashion • Followed by HRCT & PFT

  37. Treatment • Immunosuppressive agents • Azathioprine • Cytoxan • Cyclosporin • Corticosteroids

  38. Corticosteroids • Mainstay of therapy for suppressing the alveolitis • IPF-40-50% may experience subjective improvement but only a 20% objective improvement • No evidence that steroids influence the natural course of ILD in the connective tissue diseases • Exception is polymyositis/dermatomyositis

  39. Lung Transplantation • Indications for Referral • Failure to medical therapy • Worsening oxygen desaturation with minimal exercise • Resting hypoxemia • Worsening pulmonary function testing • Single Lung transplant has been standard procedure • Double Lung Transplant

  40. Idiopathic Interstitial Pneumonias • Idiopathic Interstitial pneumonias are a subset of diffuse interstitial lung disease of unknown etiology • Initially thought to be the same disease with different stages • Recognized as 4 distinct diseases with different etiologies, rate of progression, prognosis & response to therapy

  41. Idiopathic Interstitial Pneumonias • Idiopathic Interstitial pneumonias have been recently reclassified into 4 categories • Usual Interstitial Pneumonia (UIP) • Nonspecific interstitial pneumonia (NSIP) • Desquamative interstitial pneumonia • Acute interstitial pneumonia

  42. Usual Interstitial Pneumonia (UIP) • Term is synonymous with IPF • Cause is unknown • Estimated prevalence of 14 to 42 per 100,000 • Men > Female • Mortality increased from 1992 to 2003 • 49.7 to 64.3 deaths per 1000 men • 42.3 to 58.4 deaths per 1000 women • Average survival is 3 years from time of diagnosis

  43. Usual Interstitial Pneumonia (UIP) • Pulmonary function typically demonstrates a restrictive pattern & CXR reveals diffuse interstitial opacities associated with reduced lung volumes • HRCT demonstrates a peripheral & bibasilar reticulonodular opacities

  44. Usual Interstitial Pneumonia (UIP) • Disease generally does not respond to prednisone alone –given but usually don’t respond • No therapy has proven to be effective • Current therapies include prednisone & azathioprin, cytoxan, mycophenolate (cellcept) • Lung transplant may improve survival in selected patients

  45. Nonspecific Interstitial Pneumonia (NSIP) • NSIP maybe idiopathic or a manifestation of connective tissue-ILD, hypersensitivity pneumonitis, or drug reaction • 2 pathologic subtypes: cellular & fibrotic • Survival for cellular NSIP >10yrs • Survival for fibrotic NSIP is 5yrs

  46. Nonspecific Interstitial Pneumonia • Cellular NSIP typically responds to prednisone • Therapy for fibrotic NSIP is same as cellular NSIP, but less clear

  47. Desquamative Interstitial Pneumonia • Similar to Respiratory bronchiolitis interstitial lung disease (RBILD) • Smoking causes this disease • Typically resolves with smoking cessation • Some pts may require treatment with prednisone

  48. Acute Interstitial Pneumonia • AIP presents with explosive onset of respiratory symptoms & characterized by rapid progressive respiratory failure associated with diffuse infiltrates • Similar to ARDS, differing only in that it is not preceded by catastrophic event • Pathology reveals diffuse alveolar damage • May respond to prednisone, however relapses are frequent • In hospital mortality is 33%

More Related